2024-09-05T12:27:06-05:00 2023-12-31 WITHUMSMITHBROWNPC 4600 EAST WEST HWY 900 BETHESDA MD 208143423 990 2023-01-01 042531031 NATIONAL FOUNDATION FOR CANCER RESEARCH % KWOK LEUNG NATI 3016541250 5515 SECURITY LANE Suite 1105 ROCKVILLE MD 20852 SUJUAN BA PRESIDENT & CEO 3016541250 2024-09-04 true true RICHARD RUVELSON P00234075 3012726000 2023 2024-08-08 14:25:15Z SUJUAN BA 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 9866139 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 5 5 16 5 0 0 8181991 8681414 0 0 138215 370595 87853 110433 8408059 9162442 2285179 3445964 0 0 2194753 1910593 31557 31582 1766659 3973419 4402392 8484908 9790531 -76849 -628089 10719078 10533674 3111496 2852963 7607582 7680711 X SEE SCHEDULE O false false 4781528 3445964 CANCER RESEARCH - SEE SCHEDULE O 2400565 CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O 7182093 true true false false false true false false false true true false false true true true false true false false true true true true true false false true true true false false false false false false false false false false false false false true true false false false true 23 0 true 16 true false false false false false true true false false false false false false false false false X 5 5 false false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X KWOK LEUNG 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 X SUJUAN BA PRESIDENT/CEO 40.0 0.0 X 471385 0 81925 KWOK LEUNG CFO/SECRETARY 40.0 0.0 X 204079 0 30434 BRIAN WACHTEL EXECUTIVE DIRECTOR 40.0 0.0 X 151108 0 17381 ZETING WANG SR. DIR OF DIRECT RESPONSE 40.0 0.0 X 124087 0 11940 ALFRED SLANETZ CHAIR OF THE BOARD 5.0 0.0 X X 0 0 0 BRIAN LEYLAND-JONES TREASURER 2.0 0.0 X X 0 0 0 JUDITH P BARNHARD DIRECTOR 1.5 0.0 X 0 0 0 KAREN BURKE DIRECTOR 1.5 0.0 X 0 0 0 LANCE KAWAGUCHI DIRECTOR 1.0 0.0 X 0 0 0 Edward s west Director (THRU 04/26/2023) 1.0 0.0 X 0 0 0 950659 0 141680 4 false true false AMERGENT INC 9 CENTENNIAL DRIVE PEABODY MA 01960 CONSULTING & MNGT 368979 REDFIELD DIRECT LLC 11422 MIRACLE HILLS DR 450 OMAHA NE 68154 LABEL PRINTING 355456 CENVEO WORLDWIDE LIMITED ROUTE 866 PO DRAWER C WILLIAMBURG PA 16693 ENVELOPE PRINTING 322521 CALMARK GROUP LLC 6755 SAYRE AVE BEDFORD PARK IL 60638 MAIL SHOP 322350 LARSEN MARKETING GROUP 6236 WILMETTE BURKE VA 22015 CONSULTING 169088 7 43437 289157 8348820 11849 8681414 0 246067 246067 0 6870 6870 0 0 0 783438 658910 124528 124528 124528 45973 289157 44787 1186 1186 0 0 0 0 0 0 MAILING LIST RENTALS 541800 102377 102377 102377 9162442 481028 3116805 3116805 204159 204159 125000 125000 0 791882 613305 173028 5549 0 880499 596421 125253 158825 82727 57250 8040 17437 58480 38997 11692 7791 97005 69882 17013 10110 0 39329 8209 31120 53151 53151 0 31582 31582 48176 48176 561442 236044 231794 93604 34926 2277 12219 20430 99697 30388 56491 12818 531620 306464 5402 219754 0 235264 169328 41357 24579 69688 47191 20596 1901 0 93018 93018 0 0 8876 6395 1558 923 24117 17362 4239 2516 DIRECT MAIL PROGRAMS 2494465 1379960 1114505 LOCK BOX SERVICE 90637 54300 36337 PROCESS FEES-LIST SALES 15836 9338 6498 MISCELLANEOUS FUNDRAISING 2150 650 1500 9790531 7182093 841779 1766659 X 2879259 1775267 1103992 1162 1337 1976379 1752406 0 0 58323 51727 0 0 0 0 0 0 0 0 483323 373197 226556 206364 29069 20192 4694792 4826460 200442 200442 0 0 0 0 3275588 3307913 10719078 10533674 876435 722035 1285132 1393836 135 135 0 0 0 0 0 0 0 0 0 0 949794 736957 3111496 2852963 X 4277731 4299106 3329851 3381605 7607582 7680711 10719078 10533674 -628089 701218 X false true X true false X 9898471 10990906 9444496 8181991 8681414 47197278 0 0 9898471 10990906 9444496 8181991 8681414 47197278 356054 46841224 270568 222444 276898 202224 252937 1225071 0 0 2859 0 1186 4045 301733 192317 135298 86699 102377 818424 49244818 0.95119 0.95008 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 3040 true true 6205432 3405566 62641 3351278 6322361 7190200 2206693 -605813 2585648 6205432 7784738 3290006 213641 4098185 7190200 7915837 3260266 193223 3584588 7784738 10396983 4136982 286710 6904838 7915837 0.46460 0.35310 0.18230 false false 26890 17678 9212 154284 146580 7704 45382 42106 3276 20192 AMOUNT HELD IN TRUST BY OTHERS 2658016 RIGHT OF USE ASSET 649897 3307913 0 LEASE LIABILITY 736957 736957 X PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FASB ASC 740 FOOTNOTE: The Foundation has been recognized by the Internal Revenue Service ("IRS") as exempt from income tax under Internal Revenue Code Section 501(c)(3) and related state statutes, except for income tax on unrelated business income, if any. It qualifies as a public charity under Section 509(a)(1). The Darwin Foundation has been recognized by the IRS as exempt from income tax under Section 501 (c)(3) and related state statutes, except for income tax on unrelated business income, if any. It is a supporting organization to NFCR under Section 509(a)(3). NFCR Western Chapter, a California nonprofit corporation, and NFCR Mid-Atlantic Chapter, a District of Columbia nonprofit corporation were added in 2011 by the Foundation to its roster of subordinate organizations covered under the group exemption ruling, dated April 26, 2010, issued by the Internal Revenue Service to the Foundation. Both chapters are exempt from federal and state income tax, except for income tax on unrelated business income, as organizations described under section 501 (c)(3) of the Internal Revenue Code and related state statutes. Accounting principles generally accepted in the United States of America require management to evaluate income tax positions taken and accrue an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has evaluated the income tax positions taken and concluded that as of December 31, 2023 there are no uncertain positions taken or expected to be taken that would require recognition in the consolidated financial statements. The Foundation and affiliates are subject to routine audits by taxing jurisdictions, however, there are currently no audits in progress for any tax periods. In addition, there have been no tax related interest or penalties for the periods presented in these consolidated financial statements. Should such penalties and interest be incurred, the Foundation's policy is to recognize them as general and administrative expenses on the consolidated statements of activities. true Europe (Including Iceland and Greenland) 0 0 Grantmaking 90000 Middle East and North Africa 0 0 Grantmaking 30000 East Asia and the Pacific 0 0 Grantmaking 5000 0 0 0 0 125000 125000 Europe (Including Iceland and Greenland) Research Contracts 85000 WIRE 1 0 AWARD FOR CANCER RESEARCH PROGRESS. Middle East and North Africa 1 30000 check RESEARCH REVIEW Europe (Including Iceland and Greenland) 1 5000 check RESEARCH REVIEW East Asia and the Pacific 1 5000 check false false false false false false PART I, LINE 2 Procedure for monitoring use of grants outside USA: Grant and Contract recipients are required to submit quarterly expenditure reports and annual progress reports to NFCR. X X X X X X true AMERGENT INC 9 CENTENNIAL DR PEABODY MA 01960 Counsel false 3567682 31582 3536100 3567682 31582 3536100 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WY PLAY FOR A CURE 158624 158624 4125 DAFFODILS & DIA 115973 70000 45973 10000 11845 8726 2 60533 60533 10091 335130 289157 45973 10000 11845 22942 44787 1186 true CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(c)(3) 65731 RESEARCH CONTRACTS DANA-FARBER CANCER INSTITUTE 44 BINNEY ST MAIL STOP L229 BOSTON MA 02115 042263040 501(c)(3) 220041 RESEARCH CONTRACTS UNIVERSITY OF CALIFORNIA AT SAN DIEGO PO BOX 12385 LA JOLLA CA 92093 943067788 501(c)(3) 52044 RESEARCH CONTRACTS YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(c)(3) 130000 RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 87282 RESEARCH CONTRACTS WEILL CORNELL MEDICAL COLLEGE 1300 YORK AVENUE BOX 164 NEW YORK NY 10065 150532082 501(c)(3) 85000 RESEARCH CONTRACTS UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 19104 231352685 501(C)(3) 123272 RESEARCH CONTRACTS AIM HI ACCELERATOR FUND 5515 SECURITY LN 1105 ROCKVILLE MD 20852 824322538 501(C)(3) 850000 collaboration MASSACHUSETTS GENERAL HOSPITAL P O BOX 414876 BOSTON MA 02241 041564655 501(C)(3) 268242 RESEARCH CONTRACTS OREGON HEALTH AND SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97239 237083114 501(C)(3) 128326 RESEARCH CONTRACTS JOHNS HOPKINS UNIVERSITY 3400 N CHARLES ST BALTIMORE MD 21218 520595110 501(C)(3) 108670 RESEARCH CONTRACTS UNIVERSITY OF WASHINGTON 509 OLIVE WAY SEATTLE WA 98101 916001537 501(C)(3) 33633 RESEARCH CONTRACTS NEW YORK UNIVERSITY GROSSMAN SCHOOL MED 1 PARK AVE 6TH FLOOR NEW YORK NY 10016 135562308 501(C)(3) 88675 RESEARCH CONTRACTS UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CTR 660 PARRINGTON OVAL RM 119 NORMAN OK 73019 736091755 501(C)(3) 30888 RESEARCH CONTRACTS Parthen Inst of Transformative Oncology 5515 Security Lane Rockville MD 20852 923224051 501(C)(3) 30000 Research Contracts Ovarian Cancer Research Alliance 14 Pennsylvania Plaza New York NY 10122 133806788 501(C)(3) 500000 Research Grant Henry Ford Health System 2799 West Grand Blvd Detroit MI 48202 381357020 501(C)(3) 85000 Research Contracts Icahn School of Medicine at Mount Sinai 1 Gustave L Levy Place New York NY 10029 136171197 501(C)(3) 85000 Research Contracts Umass Chan Medical School 333 South Street Shrewsbury MA 01545 043108190 501(C)(3) 85000 Research Contracts UT Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 75390 750945939 501(C)(3) 85000 Research Contracts 20 0 CANCER RESEARCH 3 149159 RESEARCH REVIEW 2 55000 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X X X false false false false false false false true false SUJUAN BA PRESIDENT/CEO 445197 0 25000 0 1188 0 58576 0 23349 0 553310 0 0 0 KWOK LEUNG CFO/SECRETARY 202891 0 0 0 1188 0 30434 0 0 0 234513 0 0 0 BRIAN WACHTEL EXECUTIVE DIRECTOR 144838 0 6000 0 270 0 17381 0 0 0 168489 0 0 0 SCHEDULE J, PART I, LINE 7 BONUSES PAID TO KWOK LEUNG, BRIAN WACHTEL, AND ZETING WANG ARE DETERMINED ON AN ANNUAL BASIS BY THE BOARD AND/OR MANAGEMENT OF NFCR. RETENTION BONUS PAID TO SUJUAN BA IS DETERMINED BY THE BOARD ON HER EMPLOYMENT CONTRACT. PART III, LINE 1 - ORGANIZATION'S MISSION: The National Foundation for Cancer Research (NFCR) is a leading public charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, cures for cancer. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major funding sources. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. Since 1973, NFCR has provided more than $415 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. NFCR is committed to fighting cancer by funding high-risk, high-impact, and potentially high-reward discoveries in the labs and transforming them into life-saving treatments for cancer patients. Through global collaboration, NFCR is making unique impacts on new, accelerated paths to a cure. NFCR envisions a world without cancer! PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS: HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ---------------------------------------------- With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead to a cure for this deadly disease. CHROMOSOME LOSS & IMMUNE RESISTANCE ------------------------------------ TERESA DAVOLI, PH.D. PREVIOUSLY SHOWED LOSS OF A SPECIFIC "P" REGION OF CHROMOSOME 9P IS MORE FREQUENT IN PATIENTS NOT RESPONDING TO IMMUNOTHERAPY. TO UNDERSTAND THE MECHANISM, HER TEAM USED CRSIPR GENE-EDITING TOOL TO MODIFY HUMAN CANCER CELL LINES TO CONTAIN THE LOSS OF REGIONS ON CHROMOSOME 9P. COMPUTATIONAL ANALYSIS DECIPHERED WHICH 9P GENES ARE CRITICAL FOR IMMUNE EVASION. IN LAB MODELS, SILVIO GUTKIND, PH.D. IS DISSECTING WHY TUMORS WITH 9P LOSS RESPOND LESS TO IMMUNOTHERAPY. THIS RESEARCH IS ENLIGHTENING HOW TUMOR CELLS EVADE THE IMMUNE SYSTEMS' RECOGNITION AND ATTACK. 9P LOSS IS A COMMON FEATURE OF SOLID TUMORS, ESPECIALLY MELANOMA AND ORAL, LUNG, AND BLADDER CANCERS. THIS RESEARCH MAY POTENTIALLY HELP IDENTIFY PATIENTS WHO WILL RESPOND TO IMMUNOTHERAPY AND IMPROVE CURRENT IMMUNOTHERAPEUTIC STRATEGIES. COMBATTING BRAIN METASTASIS IN BREAST AND OTHER CANCER -------------------------------------------------------- HER2-POSITIVE BREAST TUMORS (ABNORMAL AMOUNTS OF HER2 GROWTH PROTEIN) ARE TREATED WITH TARGETED THERAPIES BUT SOME PATIENTS DO NOT RESPOND TO TREATMENT AND DEVELOP BRAIN METASTASES WITH DISMAL OUTCOMES. KORNELIA POLYAK, M.D., PH.D. AND VALERIE WEAVER, PH.D. ARE EXPLORING HOW THE BRAIN ENVIRONMENT ENABLES BREAST CANCER CELLS TO GROW AND SURVIVE. THEIR RESULTS OPEN A NEW AND SIGNIFICANT RESEARCH FIELD. THE DATA SUGGEST THAT TARGETING SUGAR MOLECULES OR GLYCOSYLATION IN CELLS AND THE SPECIFIC INTERACTIONS BETWEEN BRAIN CELLS AND CANCER CELLS COULD IMPROVE THE OUTCOMES OF BREAST CANCER PATIENTS WITH BRAIN METASTASES. MOREOVER, THESE RESULTS ARE RELEVANT TO OTHER CANCER TYPES THAT COMMONLY METASTASIZE TO THE BRAIN INCLUDING MELANOMA AND LUNG CANCER. IMMUNOTHERAPY FOR MERKLE CELL CANCER AND OTHER VIRUS-DRIVEN CANCERS. -------------------------------------------------------------------- WHILE 50% OF PATIENTS WITH MERKEL CELL CANCER (MCC) RESPOND WELL TO IMMUNE-BASED THERAPIES, OTHERS DO NOT. AS WITH MOST CANCERS, THE BASIS FOR DIFFERENT OUTCOMES IS UNKNOWN. MERKEL CELL POLYOMAVIRUS CAUSES 80% OF MCCS WHILE 20% IS CAUSED BY UV LIGHT-INDUCED DNA MUTATIONS. EACH MCC SUBTYPE MAY BE 'SEEN' IN DIFFERENT WAYS BY THE IMMUNE SYSTEM. DRS. SUZANNE TOPALIAN AND PAUL NGHEIM ARE STUDYING GENE EXPRESSION IN TUMOR- INFILTRATING T CELLS IN PATIENTS RECEIVING IMMUNOTHERAPY. COMPUTER MODELING REVEALED A GENE EXPRESSION PROFILE DERIVED FROM LUNG CANCER MUTATION-SPECIFIC T CELLS ALSO IDENTIFIES TUMOR- SPECIFIC T CELLS IN MCC SPECIMENS. A DEEPER UNDERSTANDING OF IMMUNE CELL-TYPES IN TUMORS RESPONDING OR NOT TO IMMUNOTHERAPY IS NOW POSSIBLE. THIS RESEARCH WILL ALLOW COMBINATIONS OF EXISTING AND EMERGING THERAPIES TO HELP PATIENTS OVERCOME MCC AND OTHER VIRUS-DRIVEN CANCERS. PAIRING LUNG CANCER PATIENTS WITH THE RIGHT TREATMENT ------------------------------------------------------------------------ LUNG CANCER PATIENTS WITH MUTATIONS IN THE ALK GENE (OR ALK-POSITIVE OR ALK+) EVENTUALLY BECOME RESISTANT TO THE 1ST, 2ND, AND 3RD LINE OF STANDARD THERAPIES WITH NO OTHER AVAILABLE LIFE-SUSTAINING THERAPY. AARON HATA, M.D., PH.D. AND JESSICA LIN, M.D. ARE USING A NEW BREAKTHROUGH TECHNOLOGY THAT IDENTIFIES AND QUANTIFIES THE GENES IN PRESERVED BIOPSY SAMPLES, A METHOD NOT PREVIOUSLY POSSIBLE. A DEEPER UNDERSTANDING OF HOW CANCERS CHANGE WITH TARGETED THERAPIES CAN POTENTIALLY NOMINATE NEW WAYS TO TREAT RESISTANT CANCERS AND SAVE LIVES. Predicting Why Cancer Spreads in Some Patients ------------------------------------------------ DANNY WELCH, PH.D. AND ISIDORE RIGOUTSOS, PH.D. ARE FINDING VARIABILITIES IN A SHORT FORM OF RNA IN THE MITOCHONDRIA, THE CELL PART THAT PRODUCES OUR BODY'S ENERGY, POSSIBLY EXPLAINING WHY CANCER SPREADS IN SOME PATIENTS BUT NOT IN OTHERS. THE RNA MAY PARTIALLY EXPLAIN RACIAL DISPARITIES IN CANCER RATES AND SEVERITY. THEIR RESEARCH SUGGESTS THAT A SIMPLE BLOOD TEST COULD GUIDE DOCTORS TO AGGRESSIVELY TREAT PATIENTS WHOSE CANCER MAY SPREAD OR SPARE PATIENTS AT LOW RISK FROM UNDERGOING TREATMENTS WITH HARSH SIDE EFFECTS. CAR-T Cell Immunotherapy for Pancreatic Cancer ----------------------------------------------- THERE ARE NO EFFECTIVE CAR-T CELL THERAPIES (OR T CELL-BASED IMMUNOTHERAPIES) FOR PANCREATIC CANCER. AVERY POSEY, PH.D. AND COURTNEY HOUCHEN, M.D. ARE DEVELOPING CAR-T CELLS THAT TARGET TWO TUMOR-ASSOCIATED PROTEINS CONTRIBUTING TO IMMUNE SUPPRESSION. THIS APPROACH MAY ENHANCE THE ANTI-TUMOR EFFICACY OF THESE CAR-T CELLS AND PREVENT TUMOR ESCAPE. THIS WORK IS IDENTIFYING THE MOST PROMISING CANDIDATES FOR FUTURE CLINICAL STUDIES - GIVING PANCREATIC PATIENTS HOPE FOR A NEW TREATMENT. NEW FOCUS: Early Detection & Intervention ------------------------------------------- A new NFCR focuses on early cancer detection, early-stage cancer intervention, and treatment. We are supporting a group of leading-edge scientists pioneering and investigating innovative approaches to stop cancers at their early stage, such as stage zero, and to detect them before new cancer happens. Dr. Azra Raza, a distinguished trailblazer, particularly in hematology and oncology, seeks to identify elusive biomarkers that serve as harbingers of cancer, allowing for timely intervention when the disease is most amenable to treatment. Her work has shed light on the role of abnormally large cells in cancer development and progression. It has opened new avenues for therapeutic interventions and diagnostic strategies in the battle against cancer. Dr. Siddhartha Mukherjee's research focuses on the microenvironment in the bone marrow where bone-stem cells signal and regulate the development of blood stem cells. By unraveling these key signals, he aims to identify changes that might signal dangerous blood cancers like myelodysplastic syndrome and leukemia at an earlier stage. By developing and improving screening tests to find and diagnose cancer at its earliest, most treatable stages, scientists are working to reduce overall cancer risk and prevent the disease from developing. We will kill cancers before they kill people. Our goal is to reduce cancer incidences and increase cancer survivors. New Research Program: Expanding Powerful Detection Technology for Many Cancers ----------------------------------------------------------------------- ADVANCED AND METASTATIC CANCER TAKES THE LIVES OF MORE THAN 90% OF PATIENTS. EARLY DETECTION OF CANCER AND ITS PROGRESSION IS A DIRE UNMET NEED FOR PATIENTS, FAMILIES, AND THE CANCER RESEARCH COMMUNITY. NFCR'S NEW INITIATIVE FOCUSES ON CANCER CELL DIAGNOSTIC TECHNOLOGY TO PROVIDE AN INCREASED UNDERSTANDING OF LIVE CANCER CELLS OR CIRCULATING TUMOR CELLS (CTCS) IN REAL-TIME AND AN INCLUSIVE UNDERSTANDING OF THE TUMOR MICROENVIRONMENT AT THE CELLULAR, GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC LEVELS. TEN LEADING RESEARCHERS FROM ACROSS THE GLOBE HAVE BEGUN TO GENERATE THE KNOWLEDGE NEEDED TO ACCELERATE THIS MOST CRITICAL CANCER PROBLEM FOR CANCER PATIENTS OF EARLY DETECTION AND MONITORING OF ADVANCED CANCER. Botanical Drug Treating Patients in Clinical Trials ----------------------------------------------------- Over two decades of funding from NFCR supporters helped Yung-Chi Cheng, Ph.D. and his team develop YIV-906, a botanical drug with holistic and multiple system anti-cancer properties that enhance immunotherapy and chemotherapy. NFCR's AIM-HI Translational Research Initiative support facilitated the translation of YIV-906 to reach the clinical stages. Now, a phase I/ii global clinical trial is treating liver cancer patients with YIV-906 combined with a frontline drug. Since YIV-906 also protects the gastrointestinal tract from harsh side effects of many therapies, the botanical should alleviate adverse effects of the frontline drug that has caused many patients to discontinue its use. Preliminary trends of phase i/ii trial results look promising for extending progression free survival, overall survival, quality of life and tolerability. With success in final phase clinical trials, YIV-906 could become the first U.S.-approved botanical cancer drug - a remarkable achievement. Unique Clinical Trial Gives Hope to Brain Cancer Patients ---------------------------------------------------------- A revolutionary clinical trial model, GBM AGILE, is now available to treat patients with the deadliest brain cancer, glioblastoma (GBM). Patients who have not had a new effective treatment in decades, now have hope for survival. GBM AGILE's unique design surpasses standard trials to efficiently evaluate multiple new drugs and drug combinations simultaneously. Benefits include lower cost, reduced time, and fewer patients required to PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: NFCR provides the public with free materials containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message has been mailed annually to households, reaching over 235,000 email subscribers and tens of thousands of individuals through our social media channels (Twitter and Facebook) and through our website and blogs, helps to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE 19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. PART IX, LINE 26, JOINT COSTS ALLOCATION: NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 50 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY POSTAL MAIL, EMAIL, PHONE, WEBSITE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT ABOUT CANCER AND UPHOLD ITS MISSION, AND AT THE SAME TIME TO PROVIDE FUNDRAISING OPPORTUNITIES. THE COSTS RELATED TO THESE JOINT ACTIVITIES ARE ALLOCATED, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. DARWIN FOUNDATION 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 371473821 CANCER RSRCH DC 501(C)3 509(A)(3) NFCR true false false false false false false false false false false false false false false false false false false false